A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

Background and objectives: Adalimumab (ADA), a monoclonal humanised anti-TNF antibody, is usually prescribed as a second-line treatment in paediatric Crohn's disease (CD) patients who have become unresponsive or developed intolerance to infliximab (IFX). In the case series reported, more than 7...

Full description

Bibliographic Details
Main Authors: Víctor Manuel Navas-López, Gemma Pujol-Muncunill, Enrique Llerena, María Navalón Rubio, David Gil-Ortega, Vicente Varea-Calderón, Carlos Sierra Salinas, Javier Martin-de-Carpi
Format: Article
Language:Spanish
Published: Elsevier 2018-02-01
Series:Anales de Pediatría (English Edition)
Subjects:
Adalimumab
Naive a anti-TNF
Biológicos
Enfermedad de Crohn
Niños
Infliximab
Online Access:http://www.sciencedirect.com/science/article/pii/S2341287917300637

Internet

http://www.sciencedirect.com/science/article/pii/S2341287917300637

Similar Items